Published in

Springer (part of Springer Nature), Annals of Hematology, 9(93), p. 1611-1612

DOI: 10.1007/s00277-014-2010-7

Links

Tools

Export citation

Search in Google Scholar

Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Dear Editor,Although not yet formally recognized into the World Health Organization classification [1], age-related Epstein–Barr virus positive (EBV+) B cell lymphoproliferative disorders (AR-EBVLPDs) are currently classified into four groups: (1) EBV+ reactive lymphoid hyperplasia; (2) EBV+ extranodal polymorphic lymphoproliferative disease (Poly-E); (3) EBV+ nodal polymorphic lymphoproliferative disease (Poly-N); and (4) EBV+ diffuse large B cell lymphoma [2]. EBV infection is also known to cause pure red cell aplasia (PRCA) and autoimmune hemolytic anemia (AIHA) [3].We report on a patient affected with AR-EBVLPD associated with PRCA and AIHA who was successfully treated with rituximab. In September 2011, we observed a 64-year-old man presenting with fever and enlarged lymph nodes. Upon admission, the hemoglobin level was normal, but in the following days, it decreased to 5.6 g/dl; a contemporary reduction of reticulocyte index and haptoglobin was also observed together with an incre